Our new long term hold Alexion Pharmaceuticals got a positive mention in Barron’s today (link above) which states how the biotech stock has lost half its value since 2015 but the stock can rise by 50% in the next 12 months. Wow!
Barron’s reasoning is pretty close to my own logic that I wrote about several days ago here. The stock is oversold and it trades at a hot Forward P/E of 15.25, making it one of the least expensive big-cap names in the NYSE Arca Biotech Index.
The company has awesome annual revenue growth of 31.5% for the past 5 years and does more than $3 billion in annual sales.
The company has explosive EPS growth of +162.9% year-over-year with an EPS growth of 85.2% quarter-over-quarter.
Alexion Pharmaceuticals was established in the U.S. in 1992 and became a public company in 1996. Alexion was added to the NASDAQ-100 Index in 2011 and to the Standard & Poor’s 500 Index in 2012. Their global headquarters and research operations are in New Haven, Conn. Alexion employs approximately 3,000 employees around the world to serve patients in 50 countries. Alexion has emerged as one of the world’s leading rare disease companies. Today, Alexion is advancing its rare disease pipeline, which, in addition to their complement and metabolic clinical programs, includes diverse preclinical programs across a range of therapeutic modalities.
Latest posts by Lance Jepsen
- Liberty Global Oversold Candle Over Candle Swing Setup - October 16, 2017
- Sally Beauty Holdings Swing Trade Long Setup - October 16, 2017
- USANA Health Sciences TMF Higher On Launch of New Products in Canada - October 16, 2017